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Unusual neuropathological features and
increased brain aluminium in a resident of
Camelford, UK
The possible role of aluminium in the pathogenesis of
Alzheimer’s disease (AD) has been hotly debated over
the past few decades. Although the so-called ‘alu-
minium hypothesis’ was popular in the 1970s and
1980s, it has gradually fallen out of favour in the
past few years possibly following a number of incon-
clusive and contradictory human environmental/clini-
cal studies. Nevertheless, there have from time to
time been reminders in the media of environmental
accidents; these have prevented the topic from disap-
pearing completely from public memory. One such
accident occurred on July 6th 1988 in Camelford,
Cornwall when 20 tonnes of aluminium sulphate
was mistakenly discharged into the mains water sup-
ply. Twenty thousand people were exposed to concen-
trations of aluminium which were 500–3000 times
the acceptable limit under European Union legisla-
tion. Over the subsequent years there have been UK
government inquiries into the supposed environmen-
tal impact and occasional clinical follow-up studies
documenting declining cerebral function in those
exposed to the contaminated water but very little
neuropathological data has been published. To our
knowledge, the case described here is only the second
neuropathological description.
In 1988 a 43-year-old man living in the Camelford
area of Cornwall was exposed to high concentrations of
aluminium in the water supply following the accidental
discharge. Six years later (age 49) he presented with
some memory problems which were put down to diffi-
culty in concentration. A SPECT scan, however, was
reported as normal. By the age of 55 he had definite
memory problems and indeed 5 years later he was
admitted to a nursing home. He had developed expres-
sive dysphasia with dyspraxia, poor visuospatial skills,
visual hallucinations and then myoclonic jerks. He died
at the age of 69. It was stated briefly in the clinical
notes that his mother probably had dementia. Consent
was given for retention of the brain and therefore
following a limited autopsy, the brain was removed
and half was frozen and half fixed in formalin.
The fixed left half of the brain weighed 463 g and
revealed cerebral atrophy. The half brain stem and
cerebellum weighed 81 g. Coronal slicing of the half
cerebrum confirmed cerebral atrophy, and there was
considerable softening. The hippocampus was small
and there was pallor to the locus coeruleus. The cere-
bellum appeared normal. The histology showed exten-
sive and widespread hyperphosphorylated (HP) tau
deposition (Figure 1a) in the form of neuritic plaques
(Figure 1b), neurofibrillary tangles (Figure 1b inset)
and neuropil threads and extensive Ab protein in the
form of plaques (both cored and diffuse) and amyloid
angiopathy (Figure 1c). This therefore reached an AD
modified Braak (BrainNet Europe (BNE)) stage of VI [1].
It also reached a Thal Ab phase of 5 and a frequent
CERAD neuritic plaque score [2]. In addition, there was
widespread a-synuclein Lewy body pathology extending
from the brain stem to involve frontal, temporal and
parietal neocortex (Figure 1d), thereby reaching a dif-
fuse neocortical stage of Dementia with Lewy bodies
according to McKeith criteria [3]. A number of a-synu-
clein positive (non-Papp-Lantos) glial cytoplasmic inclu-
sions (GCIs) (mainly astrocytic) were seen in the
cingulate, parietal and temporal cortex (Figure 1d
inset). There was also TDP-43 pathology in the limbic
system and extending into the neocortex (as demon-
strated by antibodies to phosphorylated (p)-TDP-43).
The TDP-43 pathology was seen in the form of neu-
ronal cytoplasmic inclusions (NCIs) (Figures 1e and f),
thin neurites (Figure 1f) and very occasional neuronal
intra-nuclear inclusions (NII) (Figure 1g). There were
also occasional GCIs. The hippocampus, frontal, pari-
etal, motor and temporal cortices showed TDP-43
pathology together with the basal ganglia, but not the
medulla or occipital cortex. The pTDP-43 staining pat-
tern most closely matched type A [4]. Therefore there
was AD pathology, Lewy body pathology and TDP-43
pathology in the brain. Whilst this combined pathology
with this intensity is somewhat unusual it is certainly
not unique. The pathological findings are summarized
in Table S1. Subsequent analysis revealed elevated
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Figure 1. Immunohistochemical features in the brain. (a) There was extensive HP-Tau immunopositivity throughout the neocortex
including here in the occipital cortex. (b) There were also numerous neuritic plaques (arrow) throughout the neocortex such as here in
the temporal lobe and there were also abundant neurofibrillary tangles (inset) as seen here in the frontal lobe. Anti -HP-Tau in (a), (b)
and (b inset). (c) There was Ab deposition in the cerebral cortex in the form of plaques as seen here, together with significant amyloid
angiopathy (arrows). Anti-Ab. (d) Numerous Lewy bodies were evident in the brain stem and limbic region but also here (arrow) in the
parietal cortex. A number of a-synuclein immunopositive glial (mainly astrocytic) cytoplasmic inclusions (inset) were also evident. Anti-
a-synuclein. (e)-(g) The immunohistochemistry for phosphorylated (p)TDP-43 revealed neuronal cytoplasmic inclusions (NCIs) in (e) the
dentate gyrus of the hippocampus (arrows) and the neocortex (f) such as here in the temporal cortex (arrows). In addition, neurites were
seen (f) (arrowheads). Very occasional neuronal intranuclear inclusions were seen in the frontal lobe (g). Anti-pTDP-43 in (e)-(g). (h)
Fluorescent image from the occipital cortex and stained with lumogallion revealing an orange- coloured deposit corresponding to
aluminium (arrow) adjacent to a plaque (defined by arrowheads). Scale Bar: (a)- 2000lm, (b) and (b inset)- 40 lm, (c) -250 lm, (d) and
(h)-35 lm, (d inset)-15 lm, (e) -25 lm (f)- 55 lm, (g) -10 lm.
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aluminium levels in the brain especially the parietal
and occipital lobes where there were levels up to 5.58
and 4.45 lg/g dry weight respectively. The median
control level derived from previous work being
1.02 lg/g dry weight [5], and those values above 2.0
considered pathologically concerning. Furthermore,
aluminium was able to be visualized as orange deposits
with a novel fluorescent method using lumogallion
(Figure 1h) and this was described in a previous publi-
cation [6]. These deposits, although mainly extracellu-
lar did not appear to consistently correspond to any
obvious pathological features [6]. DNA extraction was
carried out from the frozen tissue and analysis showed
no evidence of pathological mutations for b-Amyloid
precursor protein, presenilin 1 or 2 or progranulin.
Obviously this does not completely rule out an underly-
ing genetic cause. The Apolipoprotein E (APOE) geno-
type was found to be e4/4.
To our knowledge, there has only been one previ-
ously published account of the neuropathology in a
brain from a patient with cognitive decline who was
living in the Camelford area at the same time as the
patient described here [7]. The woman was aged 44
when the accident occurred, 58 when investigated for
mental decline and she died a year later. Interestingly,
as in our case she had suffered visual hallucinations,
and dysphasia but also had hypertonia. Neuropatholog-
ically there were few neuritic plaques or neurofibrillary
tangles; the main abnormality being amyloid angiopa-
thy. There was, however, Lewy body pathology as in
our case but here it was confined to brain stem and
limbic system. The APOE genotype in the previous case
was e4/4 as in our case. This combination is associated
with a greater risk for developing sporadic AD [8].
Three UK Government reports dealt with the Camel-
ford accident between 1989 and 2013 and the final con-
clusion stated that there was no evidence to suggest a
link between the incident and delayed health effects [9].
The interim findings had been disputed by a separate
clinical study in 1999 which suggested an association of
aluminium exposure with considerable damage to cere-
bral function [10]. This study itself was, however, criti-
cized for the manner of selection of cases [11]. Whilst
some separate environmental studies had shown an
association between dementia and high levels of alu-
minium in the water supply [12] other investigations
revealed no such link [13]. It is known that patients on
renal dialysis can develop an encephalopathy probably
due to aluminium in the water but neuropathologically
this does not show typical AD pathology and experimen-
tally at the ultrastructural level there are collections of
straight rather than AD type helical filaments [14,15].
One investigation showed that the gastrointestinal
absorption of aluminium was greater in patients with
AD than controls suggesting that the elevated brain
levels of the metal could be the effect rather than cause
of the disease [16], although it could be argued that the
resulting increase in cerebral aluminium may also exac-
erbate the disease process. To complicate the issue fur-
ther a more recent study has shown very high brain
aluminium levels in cases of familial AD [17]. In addi-
tion, there have been occasional suggested links between
aluminium and Lewy body pathology [18,19], but none
as yet reported between TDP-43 pathology and alu-
minium.
Aluminium is a relatively common metal found on
the earth’s crust. It is also a known neurotoxin and
animal experiments have revealed neurofibrillary
changes in the brains of rabbits, but often no or few
plaques but these deposits may be species specific [20].
There has been scepticism as to how close this process
resembles human AD, but there have been some
immunohistochemical similarities demonstrated such as
the presence of hyperphosphorylated tau in animal
models [21,22]. The possible mechanisms suggested for
aluminium neurotoxicity include: enhancing oxidative
stress, interfering with gene expression, affecting
cholinergic function, excitotoxicity, inducing apoptosis,
affecting the inflammatory response, increasing
oligomerization of Ab, and inducing tangle formation
[23,24]. Nevertheless, there is a body of opinion which
argues strongly against the so-called ‘aluminium
hypothesis’ in AD, stating lack of consistent reliable
and reproducible evidence [25]. Unfortunately the
debate often becomes overheated because it not only
involves scientific issues but also encompasses environ-
mental politics. An additional complication in this par-
ticular incident was that the sulphate component
appeared to cause the water supply to become acidic
(down to pH 3.9), which in turn (presumably by dis-
solving pipe linings) elevated the concentrations of
other metals such as copper, iron and lead [9,26].
These metals were not measured in the brain tissue,
but it is possible that they contributed to the neurode-
generative disease process since they all (especially
lead) have been implicated as neurotoxins.
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To our knowledge, this is only the second neu-
ropathological description from a patient who had a
neurodegenerative disease and had been a Camelford
resident in 1988. It is very surprising that there have
been so few such follow-up studies. Apart from the rel-
atively early psychometric study described [10], there
have to our knowledge been no full independent epi-
demiological analyses into the prevalence of early onset
neurodegenerative diseases in this cohort compared to
a similar rural population. Such investigations were
recommended in the conclusions to the 2013 Govern-
ment report [9]. To echo the appeal from the one previ-
ously published neuropathological case, it is important
to undertake brain examination of others exposed to
the drinking water in Camelford at that time, whenever
there is consent and the opportunity arises. The unu-
sual mixed pathology in the brain and elevated cerebral
aluminium levels in this latest case certainly does not
prove a role for aluminium in the pathogenesis of AD
or dementia in general. Indeed the predominantly dif-
ferent pathologies in the two cases studied so far could
argue against this. Similarly the APOE e4/4 genotype
in both could just point to an increased risk in develop-
ing sporadic AD. Nevertheless, one patient did not
actually develop high stage AD, the other described
here had a complex neuropathological profile and both
had Lewy body pathology and elevated aluminium
levels. It could therefore at least be argued that this
case keeps the ‘aluminium hypothesis’ debate alive.
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